<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref43">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Domachowske</surname>
    <given-names>J. B.</given-names>
   </name>
   <name>
    <surname>Khan</surname>
    <given-names>A. A.</given-names>
   </name>
   <name>
    <surname>Esser</surname>
    <given-names>M. T.</given-names>
   </name>
   <name>
    <surname>Jensen</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Takas</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Villafana</surname>
    <given-names>T.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2018</year>). 
  <article-title>Safety, tolerability, and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants</article-title>. 
  <source>Pediatr. Infect. Dis. J.</source>
  <volume>37</volume>, 
  <fpage>886</fpage>â€“
  <lpage>892</lpage>. 
  <pub-id pub-id-type="doi">10.1097/INF.0000000000001916</pub-id>, PMID: 
  <?supplied-pmid 29373476?>
  <pub-id pub-id-type="pmid">29373476</pub-id>
 </mixed-citation>
</ref>
